No real transactions

Encaleret

Research only

autosomal dominant hypocalcemia type 1 (ADH1)

Published evidence

2 publications1 exact-program1 related5 context / correction notes

Review publications

Program details

Sponsor update lists encaleret for ADH1 under Priority Review with a May 8, 2027 FDA target.

Program names
encaleret / CLTX-305
Modality
Small molecule
Indication
autosomal dominant hypocalcemia type 1 (ADH1)
Associated trial
NCT05680818
FDA target
May 8, 2027Date-only guidance; not a trading cutoff.

Publications 2

Evidence is grouped by its relationship to this program.

Search PubMed

Publication notes explain the evidence behind this program. PubMed / NCBI data notice

Coverage & interpretation
  • The exact ADH1 citation is a letter without a PubMed abstract; it is metadata-only here.
  • The additional clinical preprint concerns post-surgical hypoparathyroidism, not the ADH1 CALIBRATE population.

Exact program / indication

1 record
Exact programotherPMID 37754292

Efficacy and Safety of Encaleret in Autosomal Dominant Hypocalcemia Type 1.

The New England journal of medicine · 2023-09-28

Source metadata only: PubMed supplies no abstract for this letter. Read the linked publication before drawing conclusions about its methods or results.

Program relevance

The citation title identifies encaleret in ADH1, matching the catalog indication; PubMed provides no abstract.

Formulation / population: Encaleret in ADH1 is identified by the title; dosing and study design are not summarized from metadata.

  • Letter; no abstract supplied by PubMed.
  • Metadata-only record; results have not been inferred.

Letter / Research Support, U.S. Gov't, P.H.S.

Same compound & related evidence

1 record
Same compoundPreprintPMID 42183375

PTH-Independent CaSR Inhibition with the Oral Calcilytic Encaleret Improves Calcium Homeostasis in Post-Surgical Hypoparathyroidism: A Phase 2 Open-Label Proof-of-Concept Trial.

Research square · 2026-05-11

This open-label proof-of-concept preprint reports short-course encaleret treatment in ten adults with post-surgical hypoparathyroidism. Calcium-handling measures changed during treatment. The small, uncontrolled study addresses a different indication and has not been peer reviewed.

Program relevance

An encaleret phase 2 preprint in post-surgical hypoparathyroidism, a different indication from ADH1.

Formulation / population: Short-course oral encaleret in post-surgical hypoparathyroidism, not the ADH1 CALIBRATE population.

  • Preprint; not peer reviewed.
  • Different indication from the catalog ADH1 program.
  • The abstract prints an apparently malformed trial identifier; it is not adopted as a verified registry link.

Journal Article / Preprint

Sources

Publication and retrieval dates are shown separately. Market rules determine which evidence can resolve an outcome.

sponsor-releaseinvestor.bridgebio.com
Sponsor update lists encaleret for ADH1 under Priority Review with a May 8, 2027 FDA target.
Published
Aug 10, 2026
Retrieved
2026-10-30 02:09:48 UTC
sponsor-releaseinvestor.bridgebio.com
Sponsor describes encaleret as an orally administered small molecule targeting the calcium-sensing receptor.
Published
Jul 22, 2026
Retrieved
2026-10-30 02:09:48 UTC
clinical-trial-registryclinicaltrials.gov
Registry identifies the associated compound, condition and sponsor; trial completion is separate from FDA action.
Published
Not supplied
Retrieved
2026-10-30 02:09:48 UTC

Research identity and publications do not establish regulatory approval, clinical suitability or an executable market. Read the limits